Haemonetics (HAE) Set to Announce Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE) is set to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Haemonetics has set its FY 2024 guidance at 3.900-4.000 EPS and its FY24 guidance at $3.90-4.00 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. The firm had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. Haemonetics’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.85 earnings per share. On average, analysts expect Haemonetics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Haemonetics Stock Down 0.2 %

NYSE:HAE opened at $95.15 on Wednesday. The firm has a market capitalization of $4.83 billion, a PE ratio of 38.68, a price-to-earnings-growth ratio of 2.23 and a beta of 0.34. Haemonetics has a 52 week low of $70.74 and a 52 week high of $97.13. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The stock has a 50 day moving average of $83.22 and a 200-day moving average of $82.74.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Barrington Research reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a research report on Friday, April 12th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.